Tech Company Financing Transactions
SQZ Biotechnologies Funding Round
On 12/6/2017, SQZ Biotechnologies secured funding from JDRF T1D Fund.
Transaction Overview
Company Name
Announced On
12/6/2017
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
JDRF T1D Fund (Jonathan Behr)
Proceeds Purpose
The latest investment provide support for development of the Company's novel therapy for type 1 diabetes (T1D) aimed at retraining the immune system to not attack insulin-producing beta cells.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 Arsenal Yards Blvd.
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Website
Email Address
Overview
SQZ Biotechnologies (Nasdaq: SQZ). Many promising therapeutic modalities have limited clinical efficacy due to the challenges of delivering molecules into cells. SQZ Biotech seeks to address this fundamental problem by developing its CellSqueeze platform for use in drug discovery and clinical applications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Armon Sharei
Chief Financial Officer
Teri Loxam
Chief Medical Officer
Oliver Rosen
Chief Scientific Officer
Howard Bernstein
Vice President
Katherine Seidl
Vice President
Marija Tadin-Strapps
VP - Finance
Alex Balcom
VP - General Counsel
Larry Knopf
VP - Human Resources
David First
VP - Regulatory Affairs
Nicole D'Auteuil
Browse more venture capital transactions:
Prev: 12/6/2017: VirtualHealth venture capital transaction
Next: 12/6/2017: Lumen Bioscience venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs